ClinicalTrials.gg
CompletedNCT01047553Updated Jan 4, 2013Results posted

Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients

A Phase 3 interventional study of Formoterol (OT) in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 27 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-01-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
38th of 89
251 · median 120
Started
2009
with 1 other
Phase 3
40 of 89
1 open now
Registered
29th of 89
by date
Lead sponsor
20 of 89
AstraZeneca

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 38th largest by enrollment, is one of 2 that started in 2009, is one of 40 in phase 3, and was the 29th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study is a multicentre, open, randomised, parallel-group study with formoterol 9 μg one inhalation b.i.d, or standard COPD therapy. Standard (reference) COPD treatment arm should be the group to refer to when safety results of formoterol arm will be evaluated. 240 patients with moderate-to-severe COPD will be randomised (120 patients in the formoterol-arm and 120 patients on standard COPD therapy).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • Japanese
  • Phase 3
  • Safety
  • OT
  • Oxis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients, men or women ≥ 40 years
  • A clinical diagnosis of according to guidelines, and current COPD symptoms.
  • Post-bronchodilator \< 80% of predicted normal value and FEV1/FVC \< 70%, post-bronchodilator

Exclusion criteria

Exclusion Criteria:

  • A history and/or current clinical diagnosis of asthma and atopic diseases such as Allergic rhinitis
  • Patients who have experienced exacerbation requiring at least one of the following treatment, hospitalisation and/or a course of systemic within 4 weeks prior to the study start.
  • Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    1

    Formoterol 9 μg/dose

    Drug: Formoterol (OT)

Interventions

  • 9 μg/dose, Inhaled, twice daily for 52 weeks

    Also known as: Oxis Turbuhaler®

06

What researchers measure

Primary outcomes

  1. Clinical Laboratory Test: Haematology -Erythrocytes

    Mean change from Baseline

    Time frame: Baseline and week 52

  2. Clinical Laboratory Test: Haematology -Haemoglobin

    Change from baseline

    Time frame: Baseline and week 52

  3. Clinical Laboratory Test: Haematology-Leucocytes

    Change from baseline

    Time frame: Baseline and week 52

  4. Clinical Laboratory Test: Haematology-Platelet Count

    Change from baseline

    Time frame: Baseline and week 52

  5. Clinical Laboratory Test: Haematology Eosinophils

    Change from baseline

    Time frame: baseline and week 52

  6. Clinical Laboratory Test: Haematology Basophil

    Change from baseline

    Time frame: Baseline and week 52

  7. Clinical Laboratory Test: Haematology-Lymphocytes

    Change from baseline

    Time frame: Baseline and week 52

  8. Clinical Laboratory Test: Haematology-Monocytes

    Change from baseline

    Time frame: Baseline and week 52

  9. Clinical Laboratory Test: Haematology -Neutrophils

    Change from baseline

    Time frame: Baseline and week 52

  10. Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase

    Change from baseline

    Time frame: Baseline and week 52

  11. Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase

    Change from baseline

    Time frame: Baseline and week 52

  12. Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)

    Change from baseline

    Time frame: Baseline and week 52

  13. Clinical Laboratory Test: Clinical Chemistry-S-Creatinine

    Change from Baseline

    Time frame: Baseline and week 52

  14. Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin

    Change from baseline

    Time frame: Baseline and week 52

  15. Clinical Laboratory Test: Clinical Chemistry-S-Sodium

    Change from baseline

    Time frame: Baseline and week 52

  16. Clinical Laboratory Test: Clinical Chemistry-S-Potassium

    Change from baseline

    Time frame: Baseline and week 52

  17. Clinical Laboratory Test: Clinical Chemistry-S- Calcium

    Change from baseline

    Time frame: Baseline and week 52

  18. Clinical Laboratory Test: Clinical Chemistry-S-Albumin

    Change from baseline

    Time frame: Baseline and week 52

  19. Clinical Laboratory Test: Clinical Chemistry-S-Total Protein

    Change from baseline

    Time frame: Baseline and week 52

  20. Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)

    Change from baseline

    Time frame: Baseline and week 52

  21. Vital Signs- Sitting SBP

    Change from baseline

    Time frame: Baseline and week 52

  22. Vital Signs- Sitting DBP

    Change from baseline

    Time frame: Baseline and week 52

  23. Vital Signs - Pulse Rate

    Change from baseline

    Time frame: Baseline and week 52

  24. ECG Variables - Heart Rate

    Change from baseline

    Time frame: Baseline and week 52

  25. ECG Variables - QT Interval

    Change from baseline

    Time frame: Baseline and week 52

  26. ECG Variables - QTcB Interval

    Change from baseline

    Time frame: Baseline and week 52

  27. ECG Variables QTcF Interval

    Change from baseline

    Time frame: Baseline and week 52

  28. ECG Variables RR Interval

    Change from baseline

    Time frame: Baseline and week 52

Secondary outcomes

  1. Forced Expiratory Volume in One Second (FEV1)

    The ratio of the average value of available data for mean from Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group

    Time frame: Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization

  2. Forced Vital Capacity (FVC)

    The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group

    Time frame: Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization

  3. Morning Peak Expiratory Flow(PEF)

    The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period (14 - 18 days before Randomisation visit)and daily during 52-week randomization treatment

  4. Evening Peak Expiratory Flow (PEF)

    The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment

  5. Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

    There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment

  6. Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

    There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment

  7. Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

    There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment

  8. Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score

    The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.

    Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment

  9. Number of COPD Exacerbations Over the Treatment Period

    A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment was presented here.

    Time frame: Daily during 52-week randomization treatment

  10. Use of SABA (Salbutamol) as Reliever Medication

    The change from Run-in period average to Treatment period average for each treatment group.

    Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment

  11. St George's Respiratory Questionnaire (SGRQ) Total Score

    SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment

07

Results

Posted Jan 4, 2013

Participant flow

The first participant entered the study on 18 December 2009, and the last participant completed the study on 20 July 2011. A total of 320 participants were enrolled at 30 centers in Japan, and 251 participants who fulfilled the randomization criteria were randomized.

Participant flow — Overall Study
MilestoneFormoterolStandard Treatment
Started125126
Completed108117
Not completed179
Withdrew: Adverse event105
Withdrew: Withdrawal by subject42
Withdrew: Development of study-specific withdrawal11
Withdrew: Lost to follow-up10
Withdrew: Sever non-compliance to protocol10
Withdrew: Pi's decision01

Outcome measures

PrimaryClinical Laboratory Test: Haematology -Erythrocytes

Mean change from Baseline

Time frame:
Baseline and week 52
Reported as:
Mean · erythrocytes counts x10000/μl
Clinical Laboratory Test: Haematology -Erythrocytes
erythrocytes counts x10000/μlArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology -Erythrocytes-6.25 ± 23.8-5.2 ± 27.5
PrimaryClinical Laboratory Test: Haematology -Haemoglobin

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · g/dL
Clinical Laboratory Test: Haematology -Haemoglobin
g/dLArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology -Haemoglobin-0.29 ± 0.73-0.20 ± 1.14
PrimaryClinical Laboratory Test: Haematology-Leucocytes

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · leukocyte count/µL
Clinical Laboratory Test: Haematology-Leucocytes
leukocyte count/µLArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology-Leucocytes-132.1 ± 1535.3-289.5 ± 1284.6
PrimaryClinical Laboratory Test: Haematology-Platelet Count

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · Platelet Count x10000/μl
Clinical Laboratory Test: Haematology-Platelet Count
Platelet Count x10000/μlArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology-Platelet Count0.17 ± 3.29-0.40 ± 4.06
PrimaryClinical Laboratory Test: Haematology Eosinophils

Change from baseline

Time frame:
baseline and week 52
Reported as:
Mean · percentage of Eosinophil
Clinical Laboratory Test: Haematology Eosinophils
percentage of EosinophilArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology Eosinophils0.49 ± 2.210.45 ± 2.45
PrimaryClinical Laboratory Test: Haematology Basophil

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · percentage of Basophil
Clinical Laboratory Test: Haematology Basophil
percentage of BasophilArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology Basophil0.05 ± 0.370.01 ± 0.35
PrimaryClinical Laboratory Test: Haematology-Lymphocytes

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · percentage of Lymphocyte
Clinical Laboratory Test: Haematology-Lymphocytes
percentage of LymphocyteArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology-Lymphocytes-1.31 ± 7.86-0.43 ± 7.06
PrimaryClinical Laboratory Test: Haematology-Monocytes

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · percentage of Monocyte
Clinical Laboratory Test: Haematology-Monocytes
percentage of MonocyteArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology-Monocytes-0.01 ± 1.55-0.03 ± 1.49
PrimaryClinical Laboratory Test: Haematology -Neutrophils

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · percentage of Neutrophil
Clinical Laboratory Test: Haematology -Neutrophils
percentage of NeutrophilArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Haematology -Neutrophils1.92 ± 8.32-0.28 ± 7.64
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · U/l
Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase
U/lArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase-0.3 ± 10.04.9 ± 65.9
PrimaryClinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · U/l
Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase
U/lArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase0.4 ± 12.02.6 ± 39.3
PrimaryClinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · U/l
Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)
U/lArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)3.8 ± 44.7-4.4 ± 52.9
PrimaryClinical Laboratory Test: Clinical Chemistry-S-Creatinine

Change from Baseline

Time frame:
Baseline and week 52
Reported as:
Mean · mg/dL
Clinical Laboratory Test: Clinical Chemistry-S-Creatinine
mg/dLArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S-Creatinine0.009 ± 0.0890.021 ± 0.117
PrimaryClinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · mg/dL
Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin
mg/dLArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin0.05 ± 0.220.02 ± 0.19
PrimaryClinical Laboratory Test: Clinical Chemistry-S-Sodium

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · mEq/l
Clinical Laboratory Test: Clinical Chemistry-S-Sodium
mEq/lArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S-Sodium-0.3 ± 1.9-0.2 ± 2.0
PrimaryClinical Laboratory Test: Clinical Chemistry-S-Potassium

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · mEq/L
Clinical Laboratory Test: Clinical Chemistry-S-Potassium
mEq/LArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S-Potassium-0.15 ± 0.34-0.07 ± 0.37
PrimaryClinical Laboratory Test: Clinical Chemistry-S- Calcium

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · mg/dl
Clinical Laboratory Test: Clinical Chemistry-S- Calcium
mg/dlArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S- Calcium-0.02 ± 0.42-0.03 ± 0.35
PrimaryClinical Laboratory Test: Clinical Chemistry-S-Albumin

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · g/dl
Clinical Laboratory Test: Clinical Chemistry-S-Albumin
g/dlArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S-Albumin0.00 ± 0.280.00 ± 0.23
PrimaryClinical Laboratory Test: Clinical Chemistry-S-Total Protein

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · g/dl
Clinical Laboratory Test: Clinical Chemistry-S-Total Protein
g/dlArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry-S-Total Protein-0.05 ± 0.40-0.09 ± 0.37
PrimaryClinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · mg/dl
Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)
mg/dlArm 1 - FormoterolArm 2 - Standard Treatment
Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)-0.48 ± 4.000.07 ± 3.99
PrimaryVital Signs- Sitting SBP

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · mmHg
Vital Signs- Sitting SBP
mmHgArm 1 - FormoterolArm 2 - Standard Treatment
Vital Signs- Sitting SBP-2.1 ± 14.8-2.1 ± 16.4
PrimaryVital Signs- Sitting DBP

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · mmHg
Vital Signs- Sitting DBP
mmHgArm 1 - FormoterolArm 2 - Standard Treatment
Vital Signs- Sitting DBP-2.7 ± 8.9-3.5 ± 10.1
PrimaryVital Signs - Pulse Rate

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · beats/minute
Vital Signs - Pulse Rate
beats/minuteArm 1 - FormoterolArm 2 - Standard Treatment
Vital Signs - Pulse Rate1.5 ± 10.7-0.1 ± 10.2
PrimaryECG Variables - Heart Rate

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · beats/min
ECG Variables - Heart Rate
beats/minArm 1 - FormoterolArm 2 - Standard Treatment
ECG Variables - Heart Rate2.0 ± 11.40.6 ± 12.0
PrimaryECG Variables - QT Interval

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · milisecond
ECG Variables - QT Interval
milisecondArm 1 - FormoterolArm 2 - Standard Treatment
ECG Variables - QT Interval-2.0 ± 22.82.6 ± 26.7
PrimaryECG Variables - QTcB Interval

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · milisecond
ECG Variables - QTcB Interval
milisecondArm 1 - FormoterolArm 2 - Standard Treatment
ECG Variables - QTcB Interval2.1 ± 20.61.2 ± 22.2
PrimaryECG Variables QTcF Interval

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · milisecond
ECG Variables QTcF Interval
milisecondArm 1 - FormoterolArm 2 - Standard Treatment
ECG Variables QTcF Interval0.5 ± 15.11.7 ± 19.1
PrimaryECG Variables RR Interval

Change from baseline

Time frame:
Baseline and week 52
Reported as:
Mean · milisecond
ECG Variables RR Interval
milisecondArm 1 - FormoterolArm 2 - Standard Treatment
ECG Variables RR Interval-12.1 ± 7.2131.7 ± 124.1
SecondaryForced Expiratory Volume in One Second (FEV1)

The ratio of the average value of available data for mean from Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group

Time frame:
Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization
Reported as:
Geometric mean · percentage of baseline
Forced Expiratory Volume in One Second (FEV1)
percentage of baselineArm 1 - FormoterolArm 2 - Standard Treatment
Forced Expiratory Volume in One Second (FEV1)101.46 (68.9 to 139.2)99.42 (80.3 to 165.1)
SecondaryForced Vital Capacity (FVC)

The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group

Time frame:
Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization
Reported as:
Geometric mean · Percentage of baseline
Forced Vital Capacity (FVC)
Percentage of baselineArm 1 - FormoterolArm 2 - Standard Treatment
Forced Vital Capacity (FVC)101.62 (76.9 to 157.3)99.13 (75.3 to 163.0)
SecondaryMorning Peak Expiratory Flow(PEF)

The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period (14 - 18 days before Randomisation visit)and daily during 52-week randomization treatment
Reported as:
Mean · Liter/minute (L/min)
Morning Peak Expiratory Flow(PEF)
Liter/minute (L/min)Arm 1 - FormoterolArm 2 - Standard Treatment
Morning Peak Expiratory Flow(PEF)12.2 ± 34.97.3 ± 26.2
SecondaryEvening Peak Expiratory Flow (PEF)

The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment
Reported as:
Mean · Liter/minute (L/min)
Evening Peak Expiratory Flow (PEF)
Liter/minute (L/min)Arm 1 - FormoterolArm 2 - Standard Treatment
Evening Peak Expiratory Flow (PEF)9.6 ± 34.07.9 ± 28.2
SecondaryNight-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
Reported as:
Median · units on a scale
Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
units on a scaleArm 1 - FormoterolArm 2 - Standard Treatment
Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms0.0 ± 0.4-0.1 ± 0.6
SecondaryDaytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
Reported as:
Mean · units on a scale
Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
units on a scaleArm 1 - FormoterolArm 2 - Standard Treatment
Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms-0.2 ± 0.7-0.2 ± 0.8
SecondaryDaytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms

There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment
Reported as:
Mean · units on a scale
Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
units on a scaleArm 1 - FormoterolArm 2 - Standard Treatment
Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms-0.2 ± 0.8-0.1 ± 0.7
SecondaryTotal Chronic Obstructive Pulmonary Disease (COPD) Symptom Score

The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.

Time frame:
Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
Reported as:
Mean · units on a scale
Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score
units on a scaleArm 1 - FormoterolArm 2 - Standard Treatment
Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score-0.5 ± 1.2-0.4 ± 1.4
SecondaryNumber of COPD Exacerbations Over the Treatment Period

A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment was presented here.

Time frame:
Daily during 52-week randomization treatment
Reported as:
Number · number of exacerbations
Number of COPD Exacerbations Over the Treatment Period
number of exacerbationsArm 1 - FormoterolArm 2 - Standard Treatment
Number of COPD Exacerbations Over the Treatment Period2719
SecondaryUse of SABA (Salbutamol) as Reliever Medication

The change from Run-in period average to Treatment period average for each treatment group.

Time frame:
Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
Reported as:
Mean · Times/Day
Use of SABA (Salbutamol) as Reliever Medication
Times/DayArm 1 - FormoterolArm 2 - Standard Treatment
Use of SABA (Salbutamol) as Reliever Medication-0.2 ± 0.70.0 ± 1.1
SecondarySt George's Respiratory Questionnaire (SGRQ) Total Score

SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
Reported as:
Mean · units on a scale
St George's Respiratory Questionnaire (SGRQ) Total Score
units on a scaleArm 1 - FormoterolArm 2 - Standard Treatment
St George's Respiratory Questionnaire (SGRQ) Total Score-1.34 ± 8.48-0.57 ± 7.78

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Formoterol—20/125 (16%)54/125 (43.2%)
Standard Treatment—18/126 (14.3%)60/126 (47.6%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventFormoterolStandard Treatment
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders5/1254/126
PneumoniaInfections and infestations4/1251/126
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1252/126
Aortic DissectionVascular disorders1/1250/126
Spermatic Cord DisorderReproductive system and breast disorders1/1250/126
DepressionPsychiatric disorders1/1250/126
Chest X-Ray AbnormalInvestigations1/1250/126
Device FailureGeneral disorders1/1250/126
PalpitationsCardiac disorders1/1250/126
Myocardial IschaemiaCardiac disorders1/1250/126
Most frequent other events
Showing 10 of 25
Most frequent other events
EventFormoterolStandard Treatment
NASOPHARYNGITISInfections and infestations42/12553/126
Back PainMusculoskeletal and connective tissue disorders13/1252/126
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders9/1255/126
BronchitisInfections and infestations5/1259/126
PneumoniaInfections and infestations8/1253/126
PharyngitisInfections and infestations7/1254/126
DizzinessNervous system disorders6/1252/126
RhinitisInfections and infestations5/1252/126
ConstipationGastrointestinal disorders5/1254/126
ConjunctivitisEye disorders5/1255/126

Baseline characteristics

Age Continuous
Age Continuous(Years)FormoterolStandard TreatmentTotal
Mean70.8 (43 to 88)70.3 (50 to 83)70.6 (43 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)FormoterolStandard TreatmentTotal
Female6915
Male119117236
08

Study locations

27 sites
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Akita-shi, Akita, Japan
  • Research Site
    Chitose, Hokkaido, Japan
  • Research Site
    Obihiro, Hokkaido, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    AKO, Hyogo, Japan
  • Research Site
    Kobe-shi, Hyogo, Japan
  • Research Site
    Hitachi, Ibaraki, Japan
  • Research Site
    Tsukuba, Ibaraki, Japan
  • Research Site
    Kanazawa, Ishikawa, Japan
  • Research Site
    Sakaide, Kagawa, Japan
  • Research Site
    Fujisawa, Kanagawa, Japan
  • Research Site
    Kawasaki-shi, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Koshi, Kumamoto, Japan
  • Research Site
    Nagaoka, Niigata, Japan
  • Research Site
    Saiki-shi, Oita, Japan
  • Research Site
    Moriguchi, Osaka, Japan
  • Research Site
    Matsue, Shimane, Japan
  • Research Site
    Bunkyo, Tokyo, Japan
  • Research Site
    Chuo, Tokyo, Japan
  • Research Site
    Katsushika-ku, Tokyo, Japan
  • Research Site
    Kodaira, Tokyo, Japan
  • Research Site
    Setagaya, Tokyo, Japan
  • Research Site
    Tosima-ku, Tokyo, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Kyoto, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jan 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2010
First posted
Jan 13, 2010
Start
Dec 2009
Primary completionActual
Jan 2011
CompletionActual
Jul 2011
Results first posted
Jan 4, 2013
Last update
Jan 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01047553
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 13, 2010
Start date
Dec 2009
Primary completion
Jan 2011
Completion
Jul 2011
Results posted
Jan 4, 2013
Last update
Jan 4, 2013

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion